November 18, 2011 at 4:00 pm Debt reduction efforts must not siphon resources from medical innovation Guest columnists John Lechleiter and Chris Rivera argue that price controls being considered for the Medicare Part D prescription-drug program could hurt innovation, including in... Opinion